Oppilotech Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $74K
Latest Deal Amount
  • Investors
  • 4

Oppilotech General Information

Description

Developer of novel antibacterial compounds and antibiotics intended to work drug resistant organisms. The company's bacterial cell envelope bio-genesis and new antibacterial drugs is intended to identify potential drugs that hit the target and disrupt the cell envelope, increasing its permeability.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • London Bioscience Innovation Centre
  • 2 Royal College Street
  • London NW1 0NH
  • England, United Kingdom

Oppilotech Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oppilotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 01-Jun-2020 $74K Completed
5. Grant 01-May-2019 00000 Completed
4. Grant 01-Jan-2018 000.00 Completed
3. Grant 01-Aug-2017 00000 Completed
2. Accelerator/Incubator 30-Mar-2017 $120K Completed Startup
1. Angel (individual) Completed Startup
To view Oppilotech’s complete valuation and funding history, request access »

Oppilotech Executive Team (2)

Name Title Board Seat Contact Info
Ajay Mistry Ph.D Co-Founder & Chief Executive Officer
John George Co-Founder & Chief Scientific Officer
To view Oppilotech’s complete executive team members history, request access »

Oppilotech Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innovate UK Government 000 0000 000000 0
CARB-X University 000 0000 000000 0
Angels in Med City Angel Group Minority 000 0000 000000 0
O2h Ventures Venture Capital Minority 000 0000 000000 0
To view Oppilotech’s complete investors history, request access »